Cue Biopharma Inc reports results for the quarter ended in December - Earnings Summary

Cue Biopharma

28/03/2024 22:44

* Cue Biopharma Inc  CUE.OQ  reported a quarterly adjusted
loss
of 29 cents​​ per share for the quarter ended in December,
higher than the same quarter last year, when the company
reported EPS of -38 cents.  The mean expectation of
five analysts for the quarter was for a loss of 28 cents per
share. Wall Street expected results to range from -34 cents
to -23 cents per share.
    * Revenue rose 1,106% to $1.82 million from a year ago;
analysts
expected $1.57 million. 
    * Cue Biopharma Inc's reported EPS for the quarter was a
loss
of 29 cents​.
    * The company reported a quarterly loss of $13.43 million.
    * Cue Biopharma Inc shares had fallen by 30.3% this quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 8.3%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 5 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "strong buy"

Wall Street's median 12-month price target for Cue Biopharma Inc
is $8.00 
This summary was machine generated from LSEG data March 28 at
10:44 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2023      -0.28          -0.29          Missed
 Sep. 30 2023      -0.34          -0.24          Beat
 Jun. 30 2023      -0.30          -0.29          Beat
 Mar. 31 2023      -0.29          -0.29          Met